Gene signatures of breast cancer progression and metastasis

Breast Cancer Research

Volumn 13, Issue 1, 2011, Pages

  Rodenhiser, David I ^a,b,c   Andrews, Joseph D ^a   Vandenberg, Theodore A ^a,b   Chambers, Ann F ^a,b  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c CHILDREN S HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; AGE DISTRIBUTION; ALCOHOLISM; BASAL BREAST CANCER; BREAST CANCER; CANCER GENETICS; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CULTURAL FACTOR; DNA SEQUENCE; ENVIRONMENTAL FACTOR; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENETIC HETEROGENEITY; HEALTH CARE COST; HUMAN; HUMAN GENOME; LOSS OF FUNCTION MUTATION; LYMPH NODE METASTASIS; METASTASIS; MOLECULAR IMAGING; OBESITY; PATIENT IDENTIFICATION; POSTMENOPAUSE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROGNOSIS; RACE; RECURRENCE RISK; REVIEW; RNA SEQUENCE; SOCIAL STATUS; SOMATIC MUTATION; BREAST TUMOR; DISEASE COURSE; FEMALE; GENETICS; PATHOLOGY;

BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM METASTASIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860389800     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2791     Document Type: Review

References (78)

1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
2. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
3. Seal MD, Chia SK. What is the difference between triple-negative and basal breast cancers?. Cancer J 2010, 16:12-16. 10.1097/PPO.0b013e3181cf04be, 20164685.
4. Gabos Z, Thoms J, Ghosh S, Hanson J, Deschenes J, Sabri S, Abdulkarim B. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Res Treat 2010, 124:187-194. 10.1007/s10549-010-1135-1, 20814819.
5. Croker AK, Allan AL. Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med 2008, 12:374-390. 10.1111/j.1582-4934.2007.00211.x, 18182063.
6. Nakshatri H, Srour EF, Badve S. Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr Stem Cell Res Ther 2009, 4:50-60. 10.2174/157488809787169110, 19149630.
7. Dowsett M, Goldhirsch A, Hayes DF, Senn HJ, Wood W, Viale G. International Web-based consultation on priorities for translational breast cancer research. Breast Cancer Res 2007, 9:R81. 10.1186/bcr1798, 2246180, 18034879.
8. Stark AM, Tongers K, Maass N, Mehdorn HM, Held-Feindt J. Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases. J Cancer Res Clin Oncol 2005, 131:191-198. 10.1007/s00432-004-0629-9, 15592684.
9. Shevde LA, Samant RS, Goldberg SF, Sikaneta T, Alessandrini A, Donahue HJ, Mauger DT, Welch DR. Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Exp Cell Res 2002, 273:229-239. 10.1006/excr.2001.5452, 11822878.
10. Weigelt B, Hu Z, He X, Livasy C, Carey LA, Ewend MG, Glas AM, Perou CM, Van't Veer LJ. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 2005, 65:9155-9158. 10.1158/0008-5472.CAN-05-2553, 16230372.
11. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
12. Woelfle U, Cloos J, Sauter G, Riethdorf L, Janicke F, van Diest P, Brakenhoff R, Pantel K. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 2003, 63:5679-5684.
13. Van den Eynden GG, Van Laere SJ, Van der Auwera I, Gilles L, Burn JL, Colpaert C, van Dam P, Van Marck EA, Dirix LY, Vermeulen PB. Differential expression of hypoxia and (lymph)angiogenesis-related genes at different metastatic sites in breast cancer. Clin Exp Metastasis 2007, 24:13-23. 10.1007/s10585-006-9049-3, 17295094.
14. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524. 10.1038/nature03799, 1283098, 16049480.
15. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549. 10.1016/S1535-6108(03)00132-6, 12842083.
16. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826. 10.1056/NEJMoa041588, 15591335.
17. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009. 10.1056/NEJMoa021967, 12490681.
18. Rodenhiser DI, Andrews J, Kennette W, Sadikovic B, Mendlowitz A, Tuck AB, Chambers AF. Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays. Breast Cancer Res 2008, 10:R62. 10.1186/bcr2121, 2575535, 18638373.
19. Shinozaki M, Hoon DS, Giuliano AE, Hansen NM, Wang HJ, Turner R, Taback B. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res 2005, 11:2156-2162. 10.1158/1078-0432.CCR-04-1810, 15788661.
20. Andrews J, Kennette W, Pilon J, Hodgson A, Tuck AB, Chambers AF, Rodenhiser DI. Multi-platform whole-genome microarray analyses refine the epigenetic signature of breast cancer metastasis with gene expression and copy number. PLoS One 2010, 5:e8665. 10.1371/journal.pone.0008665, 2801616, 20084286.
21. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thürlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A, . International Breast Cancer Study Group Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 2008, 26:3006-3014. 10.1200/JCO.2007.14.9336, 18458044, International Breast Cancer Study Group.
22. Barth RJ. Histologic features predict local recurrence after breast conserving therapy of phyllodes tumors. Breast Cancer Res Treat 1999, 57:291-295. 10.1023/A:1006260225618, 10617306.
23. Diab SG, Clark GM, Osborne CK, Libby A, Allred DC, Elledge RM. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol 1999, 17:1442-1448.
24. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000, 124:966-978.
25. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 2003, 83:803-819. 10.1016/S0039-6109(03)00034-3, 12875597.
26. de Boer M, van Deurzen CH, van Dijck JA, Borm GF, van Diest PJ, Adang EM, Nortier JW, Rutgers EJ, Seynaeve C, Menke-Pluymers MB, Bult P, Tjan-Heijnen VC. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 2009, 361:653-663. 10.1056/NEJMoa0904832, 19675329.
27. Hansen NM, Grube B, Ye X, Turner RR, Brenner RJ, Sim MS, Giuliano AE. Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol 2009, 27:4679-4684. 10.1200/JCO.2008.19.0686, 19720928.
28. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182. 10.1126/science.3798106, 3798106.
29. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™). , http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
30. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312. 10.1200/JCO.2007.14.2364, 17954709.
31. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434. 10.1158/1078-0432.CCR-06-3045, 17671126.
32. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008, 26:2568-2581. 10.1200/JCO.2007.13.1748, 18487574.
33. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008, 26:3324-3330. 10.1200/JCO.2007.14.2471, 18612148.
34. Ewertz M, Jensen M-B, Gunnarsdottir K, Cold S. Effect of obesity on prognosis after early breast cancer. Presented at San Antonio Breast Cancer Symposium, Thursday, December 10 2009, General Session 1 , http://sabcs09.m2usa.com/sabcsol.html
35. Kwan ML, Kushi LH, Weltzien E, Tam EK, Castillo A, Sweeney C, Caan BJ. Alcohol consumption and breast cancer recurrence and survival among women with early-stage breast cancer: The Life After Cancer Epidemiology study. J Clin Oncol 2010, 28:4410-4416. 10.1200/JCO.2010.29.2730, 20805458.
36. Albain KS, Unger JM, Crowley JJ, Coltman CA, Hershman DL. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst 2009, 101:984-992. 10.1093/jnci/djp175, 2724852, 19584328.
37. Albain KS. Potential biologic causes of the racial survival disparity in adjuvant trials of ER positive breast cancer. J Clin Oncol (Meeting Abstracts) 2010, 28(15_suppl):511., http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/511
38. Goodwin PJ. Breast cancer, local-regional and adjuvant therapy: Discussion. ASCO 2010. , http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31397
39. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005, 23:9067-9072. 10.1200/JCO.2004.01.0454, 16172462.
40. Mallett S, Timmer A, Sauerbrei W, Altman DG. Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines. Br J Cancer 2010, 102:173-180. 10.1038/sj.bjc.6605462, 2795163, 19997101.
41. van't Veer LJ, Paik S, Hayes DF. Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol 2005, 23:1631-1635. 10.1200/JCO.2005.12.005, 15755970.
42. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319-1329. 10.1093/annonc/mdp322, 2720818, 19535820.
43. Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005, 23:2716-2725. 10.1200/JCO.2005.06.178, 15837986.
44. Ozanne EM, Braithwaite D, Sepucha K, Moore D, Esserman L, Belkora J. Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model. J Clin Oncol 2009, 27:214-219. 10.1200/JCO.2008.17.3914, 19047286.
45. Curigliano G, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N, Ghisini R, Colleoni M, Munzone E, Veronesi P, Zurrida S, Nolè F, Goldhirsch A. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009, 27:5693-5699. 10.1200/JCO.2009.22.0962, 19884553.
46. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009, 27:5700-5706. 10.1200/JCO.2009.23.2025, 2792998, 19884543.
47. Debled M, Mauriac L. Neoadjuvant chemotherapy: are we barking up the right tree?. Ann Oncol 2010, 21:675-679. 10.1093/annonc/mdq062, 20338876.
48. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28:1145-1153. 10.1200/JCO.2009.22.4725, 2834466, 20100965.
49. Franco A, Col N, Chlebowski RT. Discordance in estrogen (ER) and progestin receptor (PR) status between primary metastatic breast cancer: a meta-analysis. J Clin Oncol (Meeting Abstracts) 2004, 22(14_suppl):539.
50. Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O'Malley FP, Miller N, Andrulis IL, Brenner DM, Clemons MJ. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 2009, 29:1557-1562.
51. Idirisinghe PK, Thike AA, Cheok PY, Tse GM, Lui PC, Fook-Chong S, Wong NS, Tan PH. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. Am J Clin Pathol 2010, 133:416-429. 10.1309/AJCPJ57FLLJRXKPV, 20154280.
52. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009, 20:1953-1958. 10.1093/annonc/mdp263, 2791352, 19596702.
53. Lower EE, Glass E, Blau R, Harman S. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009, 113:301-306. 10.1007/s10549-008-9931-6, 18273700.
54. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, Clemons MJ. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol 2009, 20:1499-1504. 10.1093/annonc/mdp028, 2731014, 19299408.
55. Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmuller G, Pantel K. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 2001, 61:1890-1895.
56. Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, Löhberg CR, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker K, Kasimir-Bauer S, Wallwiener D, Pantel K. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat 2010, 124:403-412. 10.1007/s10549-010-1163-x, 20859679.
57. Riethdorf S, Müller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, von Minckwitz G, Pantel K. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010, 16:2634-2645. 10.1158/1078-0432.CCR-09-2042, 20406831.
58. Wu JM, Fackler MJ, Halushka MK, Molavi DW, Taylor ME, Teo WW, Griffin C, Fetting J, Davidson NE, De Marzo AM, Hicks JL, Chitale D, Ladanyi M, Sukumar S, Argani P. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 2008, 14:1938-1946. 10.1158/1078-0432.CCR-07-4082, 2965068, 18381931.
59. Palmieri D, Fitzgerald D, Shreeve SM, Hua E, Bronder JL, Weil RJ, Davis S, Stark AM, Merino MJ, Kurek R, Mehdorn HM, Davis G, Steinberg SM, Meltzer PS, Aldape K, Steeg PS. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res 2009, 7:1438-1445. 10.1158/1541-7786.MCR-09-0234, 2746883, 19723875.
60. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J, Steidl C, Holt RA, Jones S, Sun M, Leung G, Moore R, Severson T, Taylor GA, Teschendorff AE, Tse K, Turashvili G, Varhol R, Warren RL, Watson P, Zhao Y, Caldas C, Huntsman D, Hirst M, Marra MA, Aparicio S. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009, 461:809-813. 10.1038/nature08489, 19812674.
61. Albain KS, Paik S, van't Veer L. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast 2009, 18(Suppl 3):S141-145. 10.1016/S0960-9776(09)70290-5, 19914534.
62. Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobagyi GN. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 2008, 13:477-493. 10.1634/theoncologist.2007-0248, 18515733.
63. Parisi F, Gonzalez AM, Nadler Y, Camp RL, Rimm DL, Kluger HM, Kluger Y. Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models. Breast Cancer Res 2010, 12:R66. 10.1186/bcr2633, 3096952, 20809974.
64. Piccart-Gebhart MJ, Sotiriou C. Adjuvant chemotherapy - yes or no? Prognostic markers in early breast cancer. Ann Oncol 2007, 18(Suppl 12):xii2-7. 10.1093/annonc/mdm532, 18083699.
65. Personalized Treatment Trial for Breast Cancer Launched. , http://www.cancer.gov/newscenter/pressreleases/2006/tailorxrelease
66. Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M, . TRANSBIG consortium Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 2006, 3:540-551. 10.1038/ncponc0591, 17019432, TRANSBIG consortium.
67. Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008, 26:729-735. 10.1200/JCO.2007.14.3222, 18258980.
68. Voelkerding KV, Dames SA, Durtschi JD. Next-generation sequencing: from basic research to diagnostics. Clin Chem 2009, 55:641-658. 10.1373/clinchem.2008.112789, 19246620.
69. Reis-Filho JS. Next-generation sequencing. Breast Cancer Res 2009, 11(Suppl 3):S12. 10.1186/bcr2431, 2797692, 20030863.
70. Walsh T, Lee MK, Casadei S, Thornton AM, Stray SM, Pennil C, Nord AS, Mandell JB, Swisher EM, King MC. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci USA 2010, 107:12629-12633. 10.1073/pnas.1007983107, 2906584, 20616022.
71. NIH News Release NHGRI Seeks DNA Sequencing Technologies Fit for Routine Laboratory and Medical Use. NIH News Release., http://www.genome.gov/27527585
72. International Cancer Genome Consortium. , http://www.icgc.org
73. 1000 Genomes. A deep catalog of human genetic variation. , http://www.1000genomes.org
74. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 2010, 1805:105-117. 2814927, 19931353.
75. Di Cosimo S, Baselga J. Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Nat Rev Clin Oncol 7:139-147. 10.1038/nrclinonc.2009.234, 20125090.
76. Ling V, Chambers AF, Harris JF, Hill RP. Dynamic heterogeneity and metastasis. J Cell Physiol Suppl 1984, 3:99-103. 10.1002/jcp.1041210412, 6589232.
77. Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 2003, 3:912-920. 10.1038/nrc1233, 14740638.
78. Hsieh SM, Look MP, Sieuwerts AM, Foekens JA, Hunter KW. Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study. Breast Cancer Res 2009, 11:R75. 10.1186/bcr2412, 2790856, 19825179.